The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2−) breast cancer::When might multigene assays be of value? by Aapro, Matti et al.
 
 
University of Birmingham
The MAGIC survey in hormone receptor positive
(HR+), HER2-negative (HER2) breast cancer:
Aapro, Matti; De Laurentiis, Michelino; Rea, Daniel; Bargallo Rocha, Juan Enrique; Elizalde,
Roberto; Landherr, László; Linderholm, Barbro; Mamounas, Eleftherios; Markopoulos,
Christos; Neven, Patrick; Petrovsky, Alexander; Rouzier, Roman; Smit, Vincent; Svedman,
Christer; Schneider, Daniel; Thomssen, Christoph; Martin, Miguel
DOI:
10.1016/j.breast.2017.01.012
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Aapro, M, De Laurentiis, M, Rea, D, Bargallo Rocha, JE, Elizalde, R, Landherr, L, Linderholm, B, Mamounas, E,
Markopoulos, C, Neven, P, Petrovsky, A, Rouzier, R, Smit, V, Svedman, C, Schneider, D, Thomssen, C &
Martin, M 2017, 'The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2) breast cancer:
When might multigene assays be of value?', The Breast, vol. 33, pp. 191-199.
https://doi.org/10.1016/j.breast.2017.01.012
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Novel tools, such as multigene assays, may help to guide treatment decisions for these 
patients by providing prognostic and predictive information beyond traditional parameters. 
The global MAGIC (Multidisciplinary Application of Genomics in Clinical Practice) survey 
evaluated physicians on the following criteria: general practice patterns, chemotherapy 
decision criteria and treatment decisions for simulated breast cancer patients. Physicians with 
≥5 years’ of experience in breast cancer treatment working in multidisciplinary teams were 
invited to complete the survey. 
 
This study reports the survey results of 911 respondents (879 clinicians, 32 pathologists) from 
52 countries.  Data indicated an overall tendency to administer chemo-endocrine treatment 
rather than endocrine treatment alone. However, a substantial degree of uncertainty in 
treatment recommendations was observed for 52% of the analysed patient profiles. A high 
proportion of these patient profiles had intermediate risk features based on traditional 
parameters.  The majority of physicians indicated they wanted to use multigene assays 
clinically. The lack of reimbursement and availability were indicated as the main reasons for 
non-usage. These findings highlight the need for additional markers that are both prognostic 
and predictive of chemotherapy benefit that may support more-informed treatment decisions 
in HR+, HER2– patients with early disease. 
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Abstract  
Background  
A modest proportion of patients with early stage hormone receptor-positive (HR+), HER2-negative 
(HER2–) breast cancer benefit from adjuvant chemotherapy. Traditionally, treatment 
recommendations are based on clinical/pathologic criteria that are not predictive of chemotherapy 
benefit. Multigene assays provide prognostic and predictive information that can help to make more 
informed treatment decisions. The MAGIC survey evaluated international differences in treatment 
recommendations, how traditional parameters are used for making treatment choices, and for 
which patients treating physicians feel most uncertain about their decisions.  
Methods 
The MAGIC survey captured respondents’ demographics, practice patterns, relevance of traditional 
parameters for treatment decisions, and use of or interest in using multigene assays. Using this 
information, a predictive model was created to simulate treatment recommendations for 672 
patient profiles.  
Results 
The survey was completed by 911 respondents (879 clinicians, 32 pathologists) from 52 countries. 
Chemo-endocrine therapy was recommended more often than endocrine therapy alone, but there 
was substantial heterogeneity in treatment recommendations in 52% of the patient profiles; 
approximately every fourth physician provided a different treatment recommendation. The majority 
of physicians indicated they wanted to use multigene assays clinically. Lack of 
reimbursement/availability were the main reasons for non-usage. 
Conclusions 
The survey reveals substantial heterogeneity in treatment recommendations. Physicians have 
uncertainty in treatment recommendations in a high proportion of patients with intermediate risk 
features using traditional parameters. In HR+, HER2– patients with early disease the findings 
highlight the need for additional markers that are both prognostic and predictive of chemotherapy 
benefit that may support more-informed treatment decisions. 
 
Keywords: Hormone receptor-positive, HER2-negative early breast cancer, adjuvant chemotherapy, 
multigene assay, treatment decision 
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Introduction  
Breast cancer is the malignancy with the highest incidence among women in the Western world1 but 
mortality rates have been improving over many years due to a combination of improved therapies 
and screening programs leading to detection in earlier stages of disease.2  
For patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-
negative (HER2–) early breast cancer, adjuvant chemotherapy is beneficial for only a modest 
proportion of patients.3 Despite this, a high proportion of patients are recommended adjuvant 
chemotherapy when using traditional parameters such as age, nodal status, tumor size, tumor type, 
grade, and ER status. Some of these parameters are prognostic but not predictive of chemotherapy 
benefit.4 International treatment guidelines, including the St. Gallen consensus and the European 
Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), and National 
Comprehensive Cancer Network (NCCN) guidelines, do acknowledge that many patients do not 
benefit from chemotherapy, but do not provide clear guidance on treatment recommendations for 
the large group of patients who are characterized as having intermediate risk.5-8 In the absence of 
such guidance, there is substantial heterogeneity in the treatment recommendations for this patient 
population, although the extent of this heterogeneity across different geographic regions is 
unknown. 
Multigene assays can provide prognostic information beyond traditional parameters, and in some 
cases predictive information that can help physicians and patients make more-informed adjuvant 
chemotherapy treatment decisions.9, 10 Accordingly, studies have shown that the use of multigene 
assays can lead to an overall reduction in chemotherapy utilization.11-13 Despite this, the health-
economic value of assays has been challenged by many payers in Europe.11,14,15 It is therefore 
important to establish the breast cancer patient population in which multigene assays are most 
useful. 
The worldwide Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey aimed 
to assess which treatments are recommended to patients across different countries and how 
physicians use different clinical and pathologic parameters for their decisions. In addition, the 
MAGIC survey aimed to identify breast cancer patient populations for which there is an uncertainty 
regarding treatment recommendations and where multigene assays may be of particular value.  
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Methods 
Questionnaire 
An international panel of 8 breast cancer experts developed the MAGIC survey with input from 
Genomic Health (Geneva, Switzerland) and TRM Oncology (The Hague, The Netherlands). An online 
survey Web module was developed by the SKIM Group (Rotterdam, The Netherlands). 
The survey questionnaire (see supplementary material) consisted of single-select, numeric, and 
multiple-select questions capturing respondents’ demographics, general practice patterns, relevance 
of clinical and pathologic criteria for adjuvant chemotherapy decisions, and the usage of multigene 
assays. Each respondent was also asked to indicate treatment recommendations for 24 breast 
cancer patient profiles, randomly selected from a pool of 896 different patient profiles generated by 
all possible combinations of 7 patient characteristics: age (>50, >60, >70, >80 years), tumor size (>1, 
>2, >3, >4, >5 cm), tumor grade (Grade ≥ 1, Grade ≥ 2, Grade 3)  ER expression (<1%, <10%, <30%), 
PR expression (yes vs no), Ki67 expression(≥ 14%, >20%, >30%), and lymph node status (0 or any 
positive node; 1, including isolated tumor cell or micrometastases; 2; 3; ≥4). Patient profiles with 
>20% Ki67+ tumor cells combined with a Grade 1 were excluded, as they were judged as 
biologically implausible by the expert panel and>20% Ki67+ tumor cells combined with a Grade 2 
were also excluded. . For each patient profile, respondents could choose from the following 3 
recommendations: chemotherapy in addition to endocrine treatment, endocrine treatment alone, 
and a request for more information. 
 
Eligible respondents and survey distribution 
The survey was conducted between August 2013 and January 2014. Practicing clinicians and 
pathologists who actively participated in a multidisciplinary breast cancer team, had >5 years’ 
experience in breast cancer, and personally treated >20 new breast cancer patients per year 
(practicing clinicians) or ran immunohistochemistry for progesterone receptor (PR), ER, or HER2 for 
>20 breast cancer patients per year (pathologists) were eligible to complete the survey. Practicing 
clinicians also had to be personally involved in adjuvant treatment decisions for breast cancer 
patients. A link to the survey was distributed via email by breast cancer organizations, breast cancer 
study groups, and an international network of breast cancer physicians (acknowledgment in the 
Appendix). 
 
Data analysis 
Descriptive statistical analyses of the data were performed using SPSS (IBM) and Excel (Microsoft). 
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Country-specific trends were analyzed in countries with >30 respondents. A conjoint analysis was 
used to analyze practicing clinicians’ preferences and their sensitivity for different patient features 
when making treatment decisions by ranking the relevance of the 7 patient characteristics.16 
Interaction effects between the patient characteristics were disregarded in this univariate analysis.  
A predictive model was developed to simulate the likelihood of each treatment recommendation for 
all 896 possible breast cancer patient profiles. For this multivariate analysis, the survey data were 
analyzed using hierarchical Bayes analysis to calculate a physician-level model for each treatment 
choice. When simulating a patient profile, the corresponding utilities to the patient features were 
added and converted to a preference share for each treatment option. The preference share was 
then aggregated to identify the probability of each treatment for the simulated patient.  
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Results 
Respondent demographics and general practice patterns 
In total, 911 respondents (96% practicing clinicians, 4% pathologists) from 52 countries completed 
the MAGIC survey, of which the majority (74%) resided in Europe; 14 countries had ≥30 respondents 
and qualified for analysis of country-specific trends. Over half of the respondents (54%) were 
medical oncologists, followed by surgical oncologists (21%), gynecologists (16%), radiation 
oncologists (4%), and pathologists (4%). The respondent characteristics are summarized in Table 
1.6,7, 17-21 
The majority of respondents used tools/nomograms to estimate prognosis. The usage was highest 
among the radiation oncologists (97%) and lowest among the gynecologists (74%). Adjuvant! Online 
was used most frequently by gynecologists and medical, radiation, and surgical oncologists, whereas 
Nottingham Prognostic Index was more common among pathologists and practicing clinicians of 
other specialties. Predict was the third most common nomogram, used by approximately 12% of the 
respondents. In total, 98% of respondents indicated they always or often consulted internationally 
accepted guidelines for breast cancer treatment.  
 
Consideration of clinical and pathologic criteria for treatment recommendations  
Although most respondents always or often adhered to internationally accepted breast cancer 
guidelines, simulated treatment recommendations by practicing clinicians showed that the 
likelihood of receiving adjuvant chemotherapy varied substantially across countries (Figure 1). 
Overall, 65% of the patient profiles had >50% probability of an adjuvant chemotherapy 
recommendation; this proportion was highest in Greece and Mexico (72%) and lowest in Germany 
(59%) and Switzerland (58%). Part of this heterogeneity among countries may be explained by 
differences in the cutoff of clinical and pathologic criteria at which adjuvant chemotherapy is 
recommended (Table 2). Although many differences were observed between countries, a high 
proportion of respondents strongly considered using adjuvant chemotherapy in patients with: a 
tumor size of >2 cm (35%), or a tumor grade of 3 (70%), or <10% ER+ tumor cells (47%), >20% Ki67+ 
tumor cells (34%), or at least 1 positive lymph node (39%).  
The relevance of individual patient characteristics for adjuvant chemotherapy recommendations was 
also evaluated by a conjoint analysis. Using the recommendations for random patient profiles, the 
impact of patient characteristics on practicing clinicians' treatment recommendations could be 
determined, providing insight into what drives their decisions. Outcomes of this analysis showed 
that age was the most important patient characteristic for adjuvant chemotherapy decisions, 
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followed by tumor grade, tumor size, lymph node status, and Ki67, ER, and PR expression (Figure 2). 
However, the conjoint analysis did not consider potential interactions between patient 
characteristics, while these were shown to be relevant in the individual treatment 
recommendations. For example, patients with high-risk characteristics (eg, 1–3 positive lymph nodes 
or a Grade 3 tumor) had a high predicted probability (>75%) of receiving endocrine treatment alone 
if they were older or had small (<2 cm) tumors. Conversely, patients with small, Grade 1 tumors 
were likely (>75% predicted probability) to be recommended adjuvant chemotherapy if they were 
young or had positive lymph nodes. 
 
Breast cancer profiles where a multigene assay might be of value 
To explore the heterogeneity in treatment recommendations for patients with breast cancer, patient 
profiles were ranked on a heat map according to their predicted likelihood for an adjuvant 
chemotherapy or endocrine treatment alone recommendation (Figure 3). This analysis showed 
substantial heterogeneity in the simulated treatment decisions for 52% of the patient profiles, with 
at least every fourth physician recommending a different treatment. There was a particularly high 
level of uncertainty regarding treatment decisions for 15% of the patient profiles (as detailed below), 
with <50% probability for a recommendation of both chemotherapy and endocrine therapy alone.  
For patients with only high-risk characteristics, the general consensus was to advise adjuvant 
chemotherapy; 42% of the patient profiles had ≥75% probability of receiving adjuvant 
chemotherapy. Substantially fewer patient profiles (6%) had a ≥75% probability for an endocrine 
treatment alone recommendation. The 15% of patient profiles with the greatest heterogeneity in 
treatment recommendations had predominantly intermediate-risk features by traditional 
parameters (Figure 3). 
 
Multigene assay utilization   
Of the respondents, only around half (54%) of the practicing clinicians used multigene assays (Figure 
4A). The most common reason for not using assays was lack of reimbursement, price, and lack of 
availability (Figure 4B; country-specific data are displayed in Supplementary Table 1). 
There was a pronounced difference in usage of multigene assays between respondents from 
different countries, ranging from 91% of respondents in Greece using them to 0% in Sweden (Figure 
4A). Oncotype DX® Breast Cancer Assay was used most frequently (81%), followed by MammaPrint® 
(35%), EndoPredict (7%), FEMTELLE® (5%), Prosigna (2%), and Mammostrat® (1%) (Figure 4C; 
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country-specific data are displayed in Supplementary Table 2). In all countries except Germany 
(50%), the majority of physicians currently not using multigene assays wanted to use these tests.   
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Discussion  
The MAGIC survey showed that treatment recommendations in ER+, HER2– patients are highly 
heterogeneous internationally and that there is substantial uncertainty for a large proportion of 
patients. However, there was an overall strong tendency to recommend chemotherapy rather than 
endocrine therapy alone. For the majority (52%) of ER+, HER2– early breast cancer patient profiles, 
there was substantial heterogeneity in treatment recommendations, with at least every fourth 
physician recommending a different treatment. The probability of receiving chemo-endocrine or 
endocrine treatment alone was ≤ 50% for both in 15% of patients, indicating a very high uncertainty 
regarding treatment decisions. These patient profiles often had a combination of intermediate-risk 
features by traditional parameters. Using further prognostic and predictive markers such as 
multigene assays may be particularly useful to help make more-informed treatment decisions in 
these patients, although it should be emphasized that such markers may provide useful information 
also in other patients. 
Additionally, the survey revealed large differences between countries in the use of available 
multigene assays. The Oncotype DX Breast Cancer Assay was the most frequently used assay except 
in the Netherlands and Spain, where MammaPrint was the most commonly used multigene assay. 
This is in line with results from a recent ESMO-supported survey showing that Oncotype DX Breast 
Cancer Assay was selected most frequently as a multigene assay to determine adjuvant 
chemotherapy benefit for breast cancer patients.22 The differences seen in the use of available 
multigene assays is likely due to differences in data supporting prediction of chemotherapy benefit 
that only exist for the Oncotype DX assay,9 and differences in the level of evidence supporting the 
different assays in relevant patient populations, as well as the different status of multigene assays in 
international guidelines (Table 3).5-7, 23  
Although most internationally accepted guidelines include multigene assays, there is no clear 
consensus on the precise characteristics of breast cancer patients for whom these assays should be 
used and this is a likely reason to at least some of the differences seen.5-7, 23 In the ESMO guidelines it 
is suggested that multigene assays may be considered for ER+, HER2– breast cancer patients who 
are node negative with stage 2 tumors (>2 cm tumor without extension to the chest wall and/or 
skin, and without distant metastases).6 Meanwhile, the 2013 St. Gallen consensus recommended 
usage of multigene assays in selected patients with ER+, HER2− node-negative disease, those with 1–
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3 positive nodes, and patients aged more than 35 years, as adjuvant chemotherapy was thought to 
be of uncertain indication in these patients.17 These characteristics are not clearly outlined in the 
more recent recommendations from the 2015 St. Gallen consensus.5 Genomic testing was felt to be 
unnecessary for low-risk or high-risk patients by clinicopathologic parameters, although it is 
acknowledged that the interobserver variability for grade and Ki67 is high. In the NCCN guidelines 
the usage of the Oncotype DX assay is considered for node-negative, ER+, HER2− breast cancer 
patients with primary tumors of 0.6−1 cm with unfavorable features or tumors >1 cm.7 NCCN does 
not currently consider Prosigna, EndoPredict, Breast Cancer Index (BCI), or MammaPrint as having 
sufficient evidence to support their clinical use.7 In contrast, the panel of 2015 St. Gallen consensus 
voted in favor of acknowledging that  Prosigna, EndoPredict, BCI and MammaPrint and Oncotype DX 
have a prognostic value in the first 5 years.5 The NCCN guidelines, the ASCO recommendations, and 
the 2013 St. Gallen consensus also all acknowledge that the Oncotype DX assay has predictive value 
in determining the benefit of adjuvant chemotherapy.7, 17, 23  The lack of data from prospective 
studies and real life outcome data from patients where multigene assays have been used for 
treatment decisions have for a long time been a key weakness in the evidence supporting multigene 
assays. Many physicians and reimbursement bodies have also chosen to wait with including 
multigene assays in their clinical care until such data is available. Recently, prospective outcome data 
from studies and real outcome data from large cohorts of patients where Oncotype DX has been 
included when making treatment decisions have now been reported: Data from the TAILORx study 
has recently been published.24 This study prospectively stratified the use of chemotherapy on the 
basis of the Oncotype Dx assay. This study has reported that 99.3% of the patients with low 
Oncotype Dx assay Recurrence Scores between 0-10, treated with endocrine therapy alone, were 
free of distant recurrence at 5 years further demonstrating the utility of the Oncotype Dx assay to 
identify a group of patients with an exceptionally good prognosis in the absence of chemotherapy.24 
The Plan B adjuvant study in high risk node negative and node positive patients was also recently 
published.25 The Clalit registry in Israel containing data from more than 2000 patients with node 
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negative disease reported a  risk of recurrence of 0.7% at 5 years follow up for patients with low 
Recurrence scores (less than 18) where 98% had been treated with endocrine therapy alone26 and 
the SEER database analysis including more than 40 000 pts corroborates these data with breast 
cancer specific mortality rate that is exceptionally low- only 49 events in more than 20 000 patients 
with low Recurrence Scores (less than 18).27 It should be emphasized that real life data may be 
affected by selection bias regarding in which patients the assay is ordered however.  
Prospective data for the MammaPrint assay from the MINDACT trial  have been  presented and 
published in 2016. In this randomized, phase 3 study, 6693 women with early-stage breast cancer 
were enrolled and their genomic risk was determined using the 70-gene signature and their clinical 
risk with a modified version of Adjuvant! Online. The primary goal was to assess whether, among 
patients with high-risk clinical features and a low-risk gene-expression profile who did not receive 
chemotherapy, the lower boundary of the 95% confidence interval for the rate of 5-year survival 
without distant metastasis would be 92% (i.e., the noninferiority boundary) or higher. A total of 
1550 patients (23.2%) were deemed to be at high clinical risk and low genomic risk. At 5 years, the 
rate of survival without distant metastasis in this group was 94.7% (95% confidence interval, 92.5 to 
96.2) among those not receiving chemotherapy. The absolute difference in this survival rate 
between these patients and those who received chemotherapy was 1.5 percentage points, with the 
rate being lower without chemotherapy. The authors conclude that these findings suggest that 
approximately 46% of women with breast cancer who are at high clinical risk might not require 
chemotherapy.28 
Published before the above mentioned trials, the ASCO Biomarkers guidelines panel found sufficient 
evidence of clinical utility for the biomarker assays Oncotype DX, EndoPredict, PAM50, Breast Cancer 
Index, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific 
subgroups of breast cancer. 29 The panelists indicate also that treatment decisions should consider 
disease stage, comorbidities, and patient preferences.Parameters such as nodal status, tumor size 
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have been shown to add prognostic value to genomic information generated in both Oncotype DX, 
Endopredict and PAM50 . 30-32 
 
The MAGIC survey results are based on respondents’ answers indicating certain trends and not on 
objective analyses of actual treatment recommendations, which may be considered a limitation of 
this study. In addition, some of the subgroup analyses are based on small group sizes. Nevertheless, 
the large number of respondents varying in their specialty, level of experience, and country of origin 
provided a unique opportunity to compare physician subgroups. Insights into the current differences 
in general practice patterns may be valuable when developing international guidelines for breast 
cancer treatment 
 
. 
In conclusion, the MAGIC survey provides valuable insight into worldwide treatment 
recommendations for early breast cancer patients and the clinical and pathologic criteria used for 
these decisions. The overall findings indicate that there is substantial heterogeneity in how patients 
are treated and a substantial uncertainty in treatment recommendations for a large proportion of 
patients, highlighting an unmet need for broadly available markers, such as multigene assays, that 
can help to make more-informed treatment decisions by predicting a patient’s likelihood of benefit 
from adjuvant chemotherapy.  
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Appendix. Breast cancer organizations and study groups that participated in distribution of the link 
to the MAGIC survey. 
 
Arbeitsgemeinschaft Gynäkologische Onkologie e.V. 
Breast International Group 
Berufsverband Niedergelassener Gynakologischer Onkologen  
Breast International Group 
European Society of Breast Cancer Specialists 
European Organisation for Research and Treatment of Cancer 
Grupo Español de Investigación en Cáncer de Mama 
Gruppo Italiano Mammella (GIM) 
Hellenic Society of Breast Surgeons 
International Breast Cancer Study Group 
International Collaborative Cancer Group 
Italian Trials in Medical Oncology 
National Cancer Research Institute 
The Netherlands Association for Medical Education 
Priv-Doz Dr Med Marc Thill 
The Swedish Association of Breast Oncologists  
Grupo Español de Estudio, Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos 
United Kingdom Breast Intergroup  
Central and Eastern European Oncology Group 
European Society of Surgical Oncology 
Austrian Breast & Colorectal Cancer Study Group 
West German Study Group 
Sociedad Mexicana de Oncología 
Asociación Mexicana de Mastología 
Sociedad Argentina de Mastología 
Sociedade Brasileira de Oncologia Clínica 
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Figure Legends 
 
Figure 1. Likelihood of adjuvant chemotherapy recommendations stratified by country. Each 
practicing clinician was asked to make treatment recommendations for 24 randomly selected patient 
profiles (chemotherapy, endocrine treatment alone, or a request for more information). Based on 
their treatment recommendations a simulation model was generated to predict the probability for 
each treatment recommendation for 896 simulated patient profiles.  
 
 
Figure 2. Graphic representation of a conjoint analysis of adjuvant chemotherapy recommendations. 
The y-axis depicts a ranking of importance of various clinical and pathologic characteristics with 
regard to recommendation of chemotherapy. The x-axis depicts the index of importance for each 
patient characteristic. The relative distance between the levels indicates the relative impact on the 
recommendation. Interaction effects between the characteristics have not been considered in these 
analyses. ER, estrogen receptor; N0, lymph node negative; N1, 1–3 affected lymph nodes; PR, 
progesterone receptor. 
 
 
Figure 3. Ranking of 672 simulated breast cancer patient profiles according to their likelihood for an 
adjuvant chemotherapy or endocrine treatment alone recommendation. Patient profiles having the 
biologically uncommon combination of low ER expression and high PR expression or >20% Ki67+ 
tumor cells in a Grade 1 or 2 tumor were excluded from this analysis. Grey cells (n=43) show patient 
profiles with ≥75% probability to be recommended endocrine treatment alone. Orange cells (n=99) 
show patient profiles with 50%–75% probability to be recommended endocrine treatment alone. 
Purple cells (n=104) show patient profiles with <50% probability to be recommended endocrine 
treatment alone AND <50% probability to be recommended chemotherapy. Green cells (n=145) 
show patient profiles with 50%–75% probability to be recommended chemotherapy. Blue cells 
(n=281) show patient profiles with ≥75% probability to be recommended chemotherapy. ER, 
estrogen receptor; HR, hormone receptor; N0, lymph node negative; N1, 1–3 affected lymph nodes; 
PR, progesterone receptor. 
 
 
Figure 4. (A) Usage of multigene assays and desire to use multigene assays for practicing clinicians by 
country. (B) Type of multigene assays that were used (multiple answers were allowed; only 
practicing clinicians who indicated to use multigene assays were considered). (C) Reasons for not 
using multigene assays (multiple answers were allowed; only practicing clinicians who indicated to 
not use multigene assays were considered). 
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Tables 
 
Table 1. Demographics and general practice patterns of MAGIC survey respondents. 
 
 All 
respondents 
(n=911) 
Medical 
oncologists 
(n=495) 
Gynecologists 
(n=147) 
Radiation 
oncologists 
(n=38) 
Surgical 
oncologists 
(n=192) 
Pathologists 
(n=32)a 
Other (n=7) 
Region of residence, n(%)b 
 Europe 672 (74) 392 (79) 85 (58) 32 (84) 132 (69) 25 (78) 6 (86) 
 Latin America 157 (17) 44 (9) 62 (42) 4 (11) 45 (23) 1 (3) 1 (14) 
 Russia 56 (6) 46 (9) 0 (0) 0 (0) 5 (3) 5 (16) 0 (0) 
 Rest of World 26 (3) 13 (3) 0 (0) 2 (5) 10 (5) 1 (3) 0 (0) 
Experience, n (%) 
 ≥10 Years of experiencec 720 (79) 392 (79) 111 (76) 34 (89) 157 (82) 23 (72) 3 (43) 
 Chemotherapy prescriber 613 (67) 492 (99) 66 (45) 19 (50) 32 (17) 2 (6) 2 (29) 
 Number of new patients/yeard 113 (150) 104 (97) 97 (73) 125 (125) 146 (266) 641 (719) 76 (58) 
Involvement of multidisciplinary team, n(%)a 
 Always 756 (83) 407 (82) 113 (77) 34 (89) 172 (90) 25 (96) 5 (71) 
 In some cases 140 (15) 86 (17) 27 (18) 4 (11) 20 (10) 1 (4) 2 (29) 
 Never 9 (1) 2 (0.4) 7 (5) 0 (0) 0 (0) 0 (0) 0 (0) 
Guidelines adherence, n(%)a 
 Always 496 (55) 251 (51) 86 (59) 19 (50) 123 (64) 14 (54) 3 (43) 
 Often 389 (43) 234 (47) 60 (41) 16 (42) 64 (33) 12 (46) 3 (43) 
 Sometimes 15 (2) 8 (2) 0 (0) 3 (8) 4 (2) 0 (0) 0 (0) 
 Never 5 (1) 2 (0.4) 1 (1) 0 (0) 1 (1) 0 (0) 1 (14) 
Guidelines used, n(%)a,e  
 St. Gallen17  353 (71) 179 (71) 63 (73) 18 (95) 82 (67) 11 (79) 0 (0) 
 ESMO6  205 (41) 131 (52) 21 (24) 10 (53) 35 (28) 7 (50) 1 (33) 
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 ASCO18 218 (44) 115 (46) 38 (44) 9 (47) 45 (37) 9 (64) 2 (67) 
 NCCN7  272 (55) 138 (55) 42 (49) 10 (53) 74 (60) 7 (50) 1 (33) 
Tools/nomograms used, n(%)a 
 Nottingham Prognostic Index19 209 (23) 86 (17) 23 (16) 9 (24) 69 (36) 17 (65) 5 (71) 
 Adjuvant! Online20  644 (71) 363 (73) 96 (65) 32 (84) 135 (70) 15 (58) 3 (43) 
 Predict21  109 (12) 59 (12) 15 (10) 9 (24) 23 (12) 2 (8) 1 (14) 
 No use of tools/nomograms 134 (15) 73 (15) 38 (26) 1 (3) 19 (10) 2 (8) 1 (14) 
Consideration of Ki67, n(%)a 
 Strong consideration  265 (29) 156 (32) 48 (33) 6 (16) 46 (24) 8 (31) 1 (14) 
 Not a predominant consideration 497 (55) 275 (56) 78 (53) 21 (55) 108 (56) 13 (50) 2 (29) 
 Little influence 48 (5) 20 (4) 14 (10) 2 (5) 10 (5) 1 (4) 1 (14) 
 Not considered 34 (4) 13 (3) 7 (5) 2 (5) 7 (4) 4 (15) 1 (14) 
 No access to Ki67 testing 61 (7) 31 (6) 0 (0) 7 (18) 21 (11) 0 (0) 2 (29) 
ASCO, American Society of Clinical Oncology; ER, estrogen receptor; ESMO, European Society for Medical Oncology; HER2, human epidermal growth factor receptor 2; NCCN, National 
Comprehensive Cancer Network; PR, progesterone receptor. 
Due to rounding of the numbers, total percentages may not equal 100%. 
a
For the categories “Involvement of multidisciplinary team,” “Guidelines adherence,” “Guidelines used,” “Tools/nomograms used,” and “Consideration of Ki67,” data were missing for 6 
pathologists.  
b
Countries with more than 30 respondents were: Argentina, Belgium, Switzerland, Germany, Spain, France, Greece, Hungary, Italy, Mexico, The Netherlands, Russia, Sweden, and the United 
Kingdom.  
c
For practicing clinicians, the number of years of experience in treating breast cancer was considered. For pathologists, the number of years in which they were involved in running diagnostic 
tests for breast cancer patients was considered. 
d
For practicing clinicians, the number of new breast cancer patients per year treated by the respondent was considered. For pathologists, the number of breast cancer patients per year for 
which the respondent runs ER/PR/HER2 immunohistochemistry was considered. For both, “mean (standard deviation)” are shown. 
e
Only respondents who indicated to always use breast cancer treatment guidelines were considered. 
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Table 2. Consideration by practicing clinicians of traditional patient characteristics for adjuvant chemotherapy recommendations. Practicing clinicians 
indicated at which level of the respective clinical or histopathologic markers they would strongly consider to recommend adjuvant chemotherapy to HR+, 
HER2– early breast cancer patients.  
 
 All 
N=879 
AR 
N=66 
BE 
N=45 
CH 
N=29 
DE 
N=54 
ES 
N=75 
FR 
N=63 
GR 
N=45 
HU 
N=28 
IT 
N=103 
MX 
N=52 
NL 
N=27 
RU 
N=52 
SE 
N=31 
UK 
N=67 
In a node-negative context, is there a specific tumor size above which you would strongly consider using adjuvant chemotherapy? 
 >1 cm 14 39 0 3 6 11 8 11 11 4 37 22 8 10 3 
 >2 cm 35 39 42 10 26 49 48 36 50 31 31 52 29 32 34 
 >3 cm 14 8 16 10 9 16 14 24 14 17 8 15 2 23 31 
 >4 cm 5 6 7 7 0 1 6 7 11 1 4 0 2 3 12 
 >5 cm 9 5 11 38 11 8 3 4 0 6 15 4 12 26 7 
 Tumor size does not affect 
decision 
22 3 24 31 48 15 21 18 14 42 6 7 48 6 12 
In a node-negative context, is there a specific tumor grade above which you would strongly consider using adjuvant chemotherapy? 
 Grade ≥1 1 0 0 0 0 0 0 0 0 0 0 0 4 0 0 
 Grade ≥2 21 6 16 10 13 25 25 42 32 10 29 44 35 19 24 
 Grade 3 70 86 80 79 81 71 68 53 64 79 56 56 44 81 73 
 Tumor grade does not affect 
decision 
8 8 4 10 6 4 6 4 4 12 15 0 17 0 3 
What percentage of ER+ cells would you consider low and would make you strongly consider using adjuvant chemotherapy in addition to hormonal 
therapy? 
 <1% 26 61 16 28 52 19 17 24 11 22 25 22 25 0 12 
 <10% 47 30 49 38 35 45 65 44 54 45 44 56 44 84 43 
 <30% 20 6 27 34 4 29 10 24 32 25 17 11 15 10 39 
 Percentage of ER+ cells does not 
affect decision 
7 3 9 0 9 7 8 7 4 8 13 11 15 6 6 
At which Ki67 percentage would you strongly consider giving adjuvant chemotherapy? 
 ≥14%  27 28 36 10 13 43 18 33 14 20 35 17 40 6 21 
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 >20%  34 31 36 48 56 31 44 36 46 37 21 17 28 45 11 
 >30%  32 31 27 38 26 27 31 29 39 39 38 17 21 42 53 
 Ki67 expression does not affect 
decision 
7 10 2 3 6 0 8 2 0 4 6 50 11 6 16 
What number of positive axillary nodes would make you strongly consider giving chemotherapy? 
 Lymph node negative 4 0 0 3 2 5 2 2 0 4 10 4 4 6 6 
 1a  39 61 27 3 22 43 40 42 39 23 48 59 58 48 34 
 2 21 17 27 14 20 25 22 24 29 18 10 15 8 35 34 
 3 11 12 16 31 22 3 14 7 7 15 13 0 10 0 6 
 ≥4 21 8 29 45 31 13 19 22 21 33 19 15 13 6 10 
 Number of positive lymph nodes 
does not affect decision 
5 3 2 3 2 11 3 2 4 7 0 7 8 3 9 
Is there an upper age limit above which you would strongly consider not giving adjuvant chemotherapy? 
 >50 years 1 3 0 0 2 1 0 2 0 5 0 0 2 0 0 
 >60 years 1 0 0 3 0 0 3 2 4 0 0 4 0 0 0 
 >70 years 17 29 11 7 11 12 21 13 14 8 15 52 15 6 19 
 >80 years 48 52 53 62 39 60 41 36 57 51 33 33 38 77 61 
 Age does not affect decision 33 17 36 28 48 27 35 47 25 36 52 11 44 16 19 
AR, Argentina, BE, Belgium; CH, Switzerland; DE, Germany; ER, estrogen receptor; ES, Spain; FR, France; GR, Greece; HER2, human epidermal growth factor receptor; HR, hormone receptor; 
HU, Hungary; IT, Italy; MX, Mexico; NL, The Netherlands; RU, Russia; SE, Sweden; UK, United Kingdom. 
Due to rounding of the numbers, total percentages may not equal 100%. Country-specific data are shown for countries with ≥30 respondents. 
a
Including isolated tumor cells or nodal micrometastases. 
  
26 
 
 
Table 3. Multigene assays – guideline recommendations. 
 
Source 
Oncotype DX 
(21-gene RT-PCR assay) 
MammaPrint 
(70-gene expression profile) 
Other multigene assays 
NCCN7   An option when 
evaluating patients with 
primary tumors 
characterized as 
─ 0.6 to 1.0 cm 
─ Unfavorable 
features or >1 cm 
─ Node negative, 
HR+, and HER2– 
(category 2A) 
 The RS may assist in 
estimating likelihood of 
recurrence and benefit 
from chemotherapy  
 
 FDA-approved for 
identifying patients with 
ER+ or ER− breast cancer 
as having a high or low 
risk of recurrence 
 Not approved for 
predicting benefit from 
adjuvant systemic 
therapy 
 
 
 Currently insufficient 
evidence to warrant 
inclusion in the 
guidelines 
 
ESMO6   Recommended for obtaining extra prognostic and/or 
predictive information that is used to complement 
pathology assessment 
 May be used to predict response to adjuvant 
chemotherapy 
  
 Not specifically 
addressed 
 
St. Gallen5   Provides prognostic and 
predictive information 
(years 1–5 and >5) 
regarding usefulness of 
adjuvant chemotherapy in 
patients with luminal 
 Has prognostic utility 
regarding adjuvant 
chemotherapy in years 
1–5. Panel rejected the 
prognostic value 
 PAM-50 ROR score, 
EndoPredict, and the 
Breast Cancer Index 
considered to be 
prognostic in years 1–5. 
The panel was equally 
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disease. Beyond 5 years, 
the Panel was divided 
almost equally on the 
prognostic value of 
Oncotype DX 
beyond 5 years divided with regard to 
the prognostic value for 
EndoPredict, Breast 
Cancer Index in years 5-
10 but acknowledged 
the prognostic value of 
PAM-50 ROR in years 5-
10. 
ASCO23   For use in newly 
diagnosed patients with 
node-negative, ER+ breast 
cancer 
 Can identify patients who 
are predicted to obtain 
the most therapeutic 
benefit from adjuvant 
tamoxifen and may not 
require adjuvant 
chemotherapy 
 High RS appears to be 
predictive of benefit with 
adjuvant chemotherapy  
 
 The clinical utility of other assays is under investigation 
 
ASCO, American Society of Clinical Oncology; ER, estrogen receptor; ESMO, European Society for Medical Oncology; FDA, US Food and Drug Administration; HER2, human epidermal growth 
factor receptor 2; HR, hormone receptor; NCCN, National Comprehensive Cancer Network; RS, recurrence score; ROR, risk of recurrence; RT-PCR, reverse transcription polymerase chain 
reaction. 
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Supplementary Table 1. Reasons for not using multigene assays, stratified by country. 
 
 All 
N=389 
AR 
N=13 
BE 
N=28 
CH 
N=13 
DE 
N=6 
ES 
N=16 
FR 
N=37 
GR 
N=3 
HU 
N=12 
IT 
N=82 
MX 
N=11 
NL 
N=3 
RU 
N=34 
SE 
N=31 
UK 
N=42 
Lack of reimbursement 45% 0% 68% 85% 67% 63% 70% 67% 67% 60% 9% 33% 15% 6% 33% 
Price 44% 92% 43% 8% 33% 25% 49% 67% 75% 33% 91% 0% 15% 39% 52% 
Lack of availability 39% 31% 25% 15% 0% 31% 14% 67% 33% 38% 55% 0% 71% 29% 60% 
Not in relevant guidelines 20% 0% 21% 0% 67% 6% 32% 0% 8% 17% 0% 0% 32% 45% 21% 
Lack of evidence 17% 8% 29% 38% 67% 6% 22% 0% 8% 12% 0% 67% 3% 39% 19% 
Other 2% 0% 4% 8% 0% 0% 3% 0% 0% 0% 0% 0% 0% 10% 0% 
AR, Argentina, BE, Belgium; CH, Switzerland; DE, Germany; ES, Spain; FR, France; GR, Greece; HU, Hungary; IT, Italy; MX, Mexico; NL, The Netherlands; RU, Russia; SE, Sweden; UK, United 
Kingdom. 
Data show the percentage of practicing clinicians who indicated to not use multigene assays (multiple answers were allowed). Country-specific data are shown for countries with ≥30 
respondents.  
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Supplementary Table 2. Multigene assays used, stratified by country (multiple answers allowed). 
 
 All 
N=471 
AR 
N=52 
BE 
N=16 
CH 
N=16 
DE 
N=48 
ES 
N=59 
FR 
N=26 
GR 
N=41 
HU 
N=15 
IT 
N=20 
MX 
N=41 
NL 
N=24 
RU 
N=10 
UK 
N=22 
Oncotype DX® Breast Cancer Assay 81% 94% 56% 94% 77% 69% 88% 100% 93% 70% 78% 17% 50% 100% 
MammaPrint® 35% 25% 31% 19% 4% 73% 8% 7% 7% 50% 73% 96% 20% 9% 
EndoPredict® 7% 0% 13% 25% 44% 0% 0% 0% 0% 0% 2% 0% 10% 0% 
FEMTELLE® 5% 0% 0% 0% 38% 0% 15% 2% 0% 0% 0% 0% 10% 0% 
Prosigna 2% 0% 0% 0% 0% 10% 4% 0% 0% 5% 2% 0% 20% 0% 
Mammostrat® 1% 4% 0% 0% 0% 0% 0% 0% 7% 0% 5% 0% 0% 0% 
Other multigene assay 2% 0% 31% 6% 2% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
AR, Argentina, BE, Belgium; CH, Switzerland; DE, Germany; ES, Spain; FR, France; GR, Greece; HU, Hungary; IT, Italy; MX, Mexico; NL, The Netherlands; RU, Russia; SE, Sweden; UK, United 
Kingdom. 
Data show the percentage of practicing clinicians who use multigene assays who indicated to use the described multigene assay. Country-specific data are shown for countries with ≥30 
respondents. Sweden was not included in this analysis as none of the Swedish respondents indicated to use multigene assays. 
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Abstract  
Background  
A modest proportion of patients with early stage hormone receptor-positive (HR+), HER2-negative 
(HER2–) breast cancer benefit from adjuvant chemotherapy. Traditionally, treatment 
recommendations are based on clinical/pathologic criteria that are not predictive of chemotherapy 
benefit. Multigene assays provide prognostic and predictive information that can help to make more 
informed treatment decisions. The MAGIC survey evaluated international differences in treatment 
recommendations, how traditional parameters are used for making treatment choices, and for 
which patients treating physicians feel most uncertain about their decisions.  
Methods 
The MAGIC survey captured respondents’ demographics, practice patterns, relevance of traditional 
parameters for treatment decisions, and use of or interest in using multigene assays. Using this 
information, a predictive model was created to simulate treatment recommendations for 672 
patient profiles.  
Results 
The survey was completed by 911 respondents (879 clinicians, 32 pathologists) from 52 countries. 
Chemo-endocrine therapy was recommended more often than endocrine therapy alone, but there 
was substantial heterogeneity in treatment recommendations in 52% of the patient profiles; 
approximately every fourth physician provided a different treatment recommendation. The majority 
of physicians indicated they wanted to use multigene assays clinically. Lack of 
reimbursement/availability were the main reasons for non-usage. 
Conclusions 
The survey reveals substantial heterogeneity in treatment recommendations. Physicians have 
uncertainty in treatment recommendations in a high proportion of patients with intermediate risk 
features using traditional parameters. In HR+, HER2– patients with early disease the findings 
highlight the need for additional markers that are both prognostic and predictive of chemotherapy 
benefit that may support more-informed treatment decisions. 
 
Keywords: Hormone receptor-positive, HER2-negative early breast cancer, adjuvant chemotherapy, 
multigene assay, treatment decision 
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Introduction  
Breast cancer is the malignancy with the highest incidence among women in the Western world1 but 
mortality rates have been improving over many years due to a combination of improved therapies 
and screening programs leading to detection in earlier stages of disease.2  
For patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-
negative (HER2–) early breast cancer, adjuvant chemotherapy is beneficial for only a modest 
proportion of patients.3 Despite this, a high proportion of patients are recommended adjuvant 
chemotherapy when using traditional parameters such as age, nodal status, tumor size, tumor type, 
grade, and ER status. Some of these parameters are prognostic but not predictive of chemotherapy 
benefit.4 International treatment guidelines, including the St. Gallen consensus and the European 
Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), and National 
Comprehensive Cancer Network (NCCN) guidelines, do acknowledge that many patients do not 
benefit from chemotherapy, but do not provide clear guidance on treatment recommendations for 
the large group of patients who are characterized as having intermediate risk.5-8 In the absence of 
such guidance, there is substantial heterogeneity in the treatment recommendations for this patient 
population, although the extent of this heterogeneity across different geographic regions is 
unknown. 
Multigene assays can provide prognostic information beyond traditional parameters, and in some 
cases predictive information that can help physicians and patients make more-informed adjuvant 
chemotherapy treatment decisions.9, 10 Accordingly, studies have shown that the use of multigene 
assays can lead to an overall reduction in chemotherapy utilization.11-13 Despite this, the health-
economic value of assays has been challenged by many payers in Europe.11,14,15 It is therefore 
important to establish the breast cancer patient population in which multigene assays are most 
useful. 
The worldwide Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey aimed 
to assess which treatments are recommended to patients across different countries and how 
physicians use different clinical and pathologic parameters for their decisions. In addition, the 
MAGIC survey aimed to identify breast cancer patient populations for which there is an uncertainty 
regarding treatment recommendations and where multigene assays may be of particular value.  
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Methods 
Questionnaire 
An international panel of 8 breast cancer experts developed the MAGIC survey with input from 
Genomic Health (Geneva, Switzerland) and TRM Oncology (The Hague, The Netherlands). An online 
survey Web module was developed by the SKIM Group (Rotterdam, The Netherlands). 
The survey questionnaire (see supplementary material) consisted of single-select, numeric, and 
multiple-select questions capturing respondents’ demographics, general practice patterns, relevance 
of clinical and pathologic criteria for adjuvant chemotherapy decisions, and the usage of multigene 
assays. Each respondent was also asked to indicate treatment recommendations for 24 breast 
cancer patient profiles, randomly selected from a pool of 896 different patient profiles generated by 
all possible combinations of 7 patient characteristics: age (>50, >60, >70, >80 years), tumor size (>1, 
>2, >3, >4, >5 cm), tumor grade (Grade ≥ 1, Grade ≥ 2, Grade 3)  ER expression (<1%, <10%, <30%), 
PR expression (yes vs no), Ki67 expression(≥ 14%, >20%, >30%), and lymph node status (0 or any 
positive node; 1, including isolated tumor cell or micrometastases; 2; 3; ≥4). Patient profiles with 
>20% Ki67+ tumor cells combined with a Grade 1 were excluded, as they were judged as 
biologically implausible by the expert panel and>20% Ki67+ tumor cells combined with a Grade 2 
were also excluded. . For each patient profile, respondents could choose from the following 3 
recommendations: chemotherapy in addition to endocrine treatment, endocrine treatment alone, 
and a request for more information. 
 
Eligible respondents and survey distribution 
The survey was conducted between August 2013 and January 2014. Practicing clinicians and 
pathologists who actively participated in a multidisciplinary breast cancer team, had >5 years’ 
experience in breast cancer, and personally treated >20 new breast cancer patients per year 
(practicing clinicians) or ran immunohistochemistry for progesterone receptor (PR), ER, or HER2 for 
>20 breast cancer patients per year (pathologists) were eligible to complete the survey. Practicing 
clinicians also had to be personally involved in adjuvant treatment decisions for breast cancer 
patients. A link to the survey was distributed via email by breast cancer organizations, breast cancer 
study groups, and an international network of breast cancer physicians (acknowledgment in the 
Appendix). 
 
Data analysis 
Descriptive statistical analyses of the data were performed using SPSS (IBM) and Excel (Microsoft). 
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Country-specific trends were analyzed in countries with >30 respondents. A conjoint analysis was 
used to analyze practicing clinicians’ preferences and their sensitivity for different patient features 
when making treatment decisions by ranking the relevance of the 7 patient characteristics.16 
Interaction effects between the patient characteristics were disregarded in this univariate analysis.  
A predictive model was developed to simulate the likelihood of each treatment recommendation for 
all 896 possible breast cancer patient profiles. For this multivariate analysis, the survey data were 
analyzed using hierarchical Bayes analysis to calculate a physician-level model for each treatment 
choice. When simulating a patient profile, the corresponding utilities to the patient features were 
added and converted to a preference share for each treatment option. The preference share was 
then aggregated to identify the probability of each treatment for the simulated patient.  
  
7 
 
Results 
Respondent demographics and general practice patterns 
In total, 911 respondents (96% practicing clinicians, 4% pathologists) from 52 countries completed 
the MAGIC survey, of which the majority (74%) resided in Europe; 14 countries had ≥30 respondents 
and qualified for analysis of country-specific trends. Over half of the respondents (54%) were 
medical oncologists, followed by surgical oncologists (21%), gynecologists (16%), radiation 
oncologists (4%), and pathologists (4%). The respondent characteristics are summarized in Table 
1.6,7, 17-21 
The majority of respondents used tools/nomograms to estimate prognosis. The usage was highest 
among the radiation oncologists (97%) and lowest among the gynecologists (74%). Adjuvant! Online 
was used most frequently by gynecologists and medical, radiation, and surgical oncologists, whereas 
Nottingham Prognostic Index was more common among pathologists and practicing clinicians of 
other specialties. Predict was the third most common nomogram, used by approximately 12% of the 
respondents. In total, 98% of respondents indicated they always or often consulted internationally 
accepted guidelines for breast cancer treatment.  
 
Consideration of clinical and pathologic criteria for treatment recommendations  
Although most respondents always or often adhered to internationally accepted breast cancer 
guidelines, simulated treatment recommendations by practicing clinicians showed that the 
likelihood of receiving adjuvant chemotherapy varied substantially across countries (Figure 1). 
Overall, 65% of the patient profiles had >50% probability of an adjuvant chemotherapy 
recommendation; this proportion was highest in Greece and Mexico (72%) and lowest in Germany 
(59%) and Switzerland (58%). Part of this heterogeneity among countries may be explained by 
differences in the cutoff of clinical and pathologic criteria at which adjuvant chemotherapy is 
recommended (Table 2). Although many differences were observed between countries, a high 
proportion of respondents strongly considered using adjuvant chemotherapy in patients with: a 
tumor size of >2 cm (35%), or a tumor grade of 3 (70%), or <10% ER+ tumor cells (47%), >20% Ki67+ 
tumor cells (34%), or at least 1 positive lymph node (39%).  
The relevance of individual patient characteristics for adjuvant chemotherapy recommendations was 
also evaluated by a conjoint analysis. Using the recommendations for random patient profiles, the 
impact of patient characteristics on practicing clinicians' treatment recommendations could be 
determined, providing insight into what drives their decisions. Outcomes of this analysis showed 
that age was the most important patient characteristic for adjuvant chemotherapy decisions, 
8 
 
followed by tumor grade, tumor size, lymph node status, and Ki67, ER, and PR expression (Figure 2). 
However, the conjoint analysis did not consider potential interactions between patient 
characteristics, while these were shown to be relevant in the individual treatment 
recommendations. For example, patients with high-risk characteristics (eg, 1–3 positive lymph nodes 
or a Grade 3 tumor) had a high predicted probability (>75%) of receiving endocrine treatment alone 
if they were older or had small (<2 cm) tumors. Conversely, patients with small, Grade 1 tumors 
were likely (>75% predicted probability) to be recommended adjuvant chemotherapy if they were 
young or had positive lymph nodes. 
 
Breast cancer profiles where a multigene assay might be of value 
To explore the heterogeneity in treatment recommendations for patients with breast cancer, patient 
profiles were ranked on a heat map according to their predicted likelihood for an adjuvant 
chemotherapy or endocrine treatment alone recommendation (Figure 3). This analysis showed 
substantial heterogeneity in the simulated treatment decisions for 52% of the patient profiles, with 
at least every fourth physician recommending a different treatment. There was a particularly high 
level of uncertainty regarding treatment decisions for 15% of the patient profiles (as detailed below), 
with <50% probability for a recommendation of both chemotherapy and endocrine therapy alone.  
For patients with only high-risk characteristics, the general consensus was to advise adjuvant 
chemotherapy; 42% of the patient profiles had ≥75% probability of receiving adjuvant 
chemotherapy. Substantially fewer patient profiles (6%) had a ≥75% probability for an endocrine 
treatment alone recommendation. The 15% of patient profiles with the greatest heterogeneity in 
treatment recommendations had predominantly intermediate-risk features by traditional 
parameters (Figure 3). 
 
Multigene assay utilization   
Of the respondents, only around half (54%) of the practicing clinicians used multigene assays (Figure 
4A). The most common reason for not using assays was lack of reimbursement, price, and lack of 
availability (Figure 4B; country-specific data are displayed in Supplementary Table 1). 
There was a pronounced difference in usage of multigene assays between respondents from 
different countries, ranging from 91% of respondents in Greece using them to 0% in Sweden (Figure 
4A). Oncotype DX® Breast Cancer Assay was used most frequently (81%), followed by MammaPrint® 
(35%), EndoPredict (7%), FEMTELLE® (5%), Prosigna (2%), and Mammostrat® (1%) (Figure 4C; 
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country-specific data are displayed in Supplementary Table 2). In all countries except Germany 
(50%), the majority of physicians currently not using multigene assays wanted to use these tests.   
10 
 
Discussion  
The MAGIC survey showed that treatment recommendations in ER+, HER2– patients are highly 
heterogeneous internationally and that there is substantial uncertainty for a large proportion of 
patients. However, there was an overall strong tendency to recommend chemotherapy rather than 
endocrine therapy alone. For the majority (52%) of ER+, HER2– early breast cancer patient profiles, 
there was substantial heterogeneity in treatment recommendations, with at least every fourth 
physician recommending a different treatment. The probability of receiving chemo-endocrine or 
endocrine treatment alone was ≤ 50% for both in 15% of patients, indicating a very high uncertainty 
regarding treatment decisions. These patient profiles often had a combination of intermediate-risk 
features by traditional parameters. Using further prognostic and predictive markers such as 
multigene assays may be particularly useful to help make more-informed treatment decisions in 
these patients, although it should be emphasized that such markers may provide useful information 
also in other patients. 
Additionally, the survey revealed large differences between countries in the use of available 
multigene assays. The Oncotype DX Breast Cancer Assay was the most frequently used assay except 
in the Netherlands and Spain, where MammaPrint was the most commonly used multigene assay. 
This is in line with results from a recent ESMO-supported survey showing that Oncotype DX Breast 
Cancer Assay was selected most frequently as a multigene assay to determine adjuvant 
chemotherapy benefit for breast cancer patients.22 The differences seen in the use of available 
multigene assays is likely due to differences in data supporting prediction of chemotherapy benefit 
that only exist for the Oncotype DX assay,9 and differences in the level of evidence supporting the 
different assays in relevant patient populations, as well as the different status of multigene assays in 
international guidelines (Table 3).5-7, 23  
Although most internationally accepted guidelines include multigene assays, there is no clear 
consensus on the precise characteristics of breast cancer patients for whom these assays should be 
used and this is a likely reason to at least some of the differences seen.5-7, 23 In the ESMO guidelines it 
is suggested that multigene assays may be considered for ER+, HER2– breast cancer patients who 
are node negative with stage 2 tumors (>2 cm tumor without extension to the chest wall and/or 
skin, and without distant metastases).6 Meanwhile, the 2013 St. Gallen consensus recommended 
usage of multigene assays in selected patients with ER+, HER2− node-negative disease, those with 1–
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3 positive nodes, and patients aged more than 35 years, as adjuvant chemotherapy was thought to 
be of uncertain indication in these patients.17 These characteristics are not clearly outlined in the 
more recent recommendations from the 2015 St. Gallen consensus.5 Genomic testing was felt to be 
unnecessary for low-risk or high-risk patients by clinicopathologic parameters, although it is 
acknowledged that the interobserver variability for grade and Ki67 is high. In the NCCN guidelines 
the usage of the Oncotype DX assay is considered for node-negative, ER+, HER2− breast cancer 
patients with primary tumors of 0.6−1 cm with unfavorable features or tumors >1 cm.7 NCCN does 
not currently consider Prosigna, EndoPredict, Breast Cancer Index (BCI), or MammaPrint as having 
sufficient evidence to support their clinical use.7 In contrast, the panel of 2015 St. Gallen consensus 
voted in favor of acknowledging that  Prosigna, EndoPredict, BCI and MammaPrint and Oncotype DX 
have a prognostic value in the first 5 years.5 The NCCN guidelines, the ASCO recommendations, and 
the 2013 St. Gallen consensus also all acknowledge that the Oncotype DX assay has predictive value 
in determining the benefit of adjuvant chemotherapy.7, 17, 23  The lack of data from prospective 
studies and real life outcome data from patients where multigene assays have been used for 
treatment decisions have for a long time been a key weakness in the evidence supporting multigene 
assays. Many physicians and reimbursement bodies have also chosen to wait with including 
multigene assays in their clinical care until such data is available. Recently, prospective outcome data 
from studies and real outcome data from large cohorts of patients where Oncotype DX has been 
included when making treatment decisions have now been reported: Data from the TAILORx study 
has recently been published.24 This study prospectively stratified the use of chemotherapy on the 
basis of the Oncotype Dx assay. This study has reported that 99.3% of the patients with low 
Oncotype Dx assay Recurrence Scores between 0-10, treated with endocrine therapy alone, were 
free of distant recurrence at 5 years further demonstrating the utility of the Oncotype Dx assay to 
identify a group of patients with an exceptionally good prognosis in the absence of chemotherapy.24 
The Plan B adjuvant study in high risk node negative and node positive patients was also recently 
published.25 The Clalit registry in Israel containing data from more than 2000 patients with node 
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negative disease reported a  risk of recurrence of 0.7% at 5 years follow up for patients with low 
Recurrence scores (less than 18) where 98% had been treated with endocrine therapy alone26 and 
the SEER database analysis including more than 40 000 pts corroborates these data with breast 
cancer specific mortality rate that is exceptionally low- only 49 events in more than 20 000 patients 
with low Recurrence Scores (less than 18).27 It should be emphasized that real life data may be 
affected by selection bias regarding in which patients the assay is ordered however.  
Prospective data for the MammaPrint assay from the MINDACT trial  have been  presented and 
published in 2016. In this randomized, phase 3 study, 6693 women with early-stage breast cancer 
were enrolled and their genomic risk was determined using the 70-gene signature and their clinical 
risk with a modified version of Adjuvant! Online. The primary goal was to assess whether, among 
patients with high-risk clinical features and a low-risk gene-expression profile who did not receive 
chemotherapy, the lower boundary of the 95% confidence interval for the rate of 5-year survival 
without distant metastasis would be 92% (i.e., the noninferiority boundary) or higher. A total of 
1550 patients (23.2%) were deemed to be at high clinical risk and low genomic risk. At 5 years, the 
rate of survival without distant metastasis in this group was 94.7% (95% confidence interval, 92.5 to 
96.2) among those not receiving chemotherapy. The absolute difference in this survival rate 
between these patients and those who received chemotherapy was 1.5 percentage points, with the 
rate being lower without chemotherapy. The authors conclude that these findings suggest that 
approximately 46% of women with breast cancer who are at high clinical risk might not require 
chemotherapy.28 
Published before the above mentioned trials, the ASCO Biomarkers guidelines panel found sufficient 
evidence of clinical utility for the biomarker assays Oncotype DX, EndoPredict, PAM50, Breast Cancer 
Index, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific 
subgroups of breast cancer. 29 The panelists indicate also that treatment decisions should consider 
disease stage, comorbidities, and patient preferences.Parameters such as nodal status, tumor size 
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have been shown to add prognostic value to genomic information generated in both Oncotype DX, 
Endopredict and PAM50 . 30-32 
 
The MAGIC survey results are based on respondents’ answers indicating certain trends and not on 
objective analyses of actual treatment recommendations, which may be considered a limitation of 
this study. In addition, some of the subgroup analyses are based on small group sizes. Nevertheless, 
the large number of respondents varying in their specialty, level of experience, and country of origin 
provided a unique opportunity to compare physician subgroups. Insights into the current differences 
in general practice patterns may be valuable when developing international guidelines for breast 
cancer treatment 
 
. 
In conclusion, the MAGIC survey provides valuable insight into worldwide treatment 
recommendations for early breast cancer patients and the clinical and pathologic criteria used for 
these decisions. The overall findings indicate that there is substantial heterogeneity in how patients 
are treated and a substantial uncertainty in treatment recommendations for a large proportion of 
patients, highlighting an unmet need for broadly available markers, such as multigene assays, that 
can help to make more-informed treatment decisions by predicting a patient’s likelihood of benefit 
from adjuvant chemotherapy.  
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Appendix. Breast cancer organizations and study groups that participated in distribution of the link 
to the MAGIC survey. 
 
Arbeitsgemeinschaft Gynäkologische Onkologie e.V. 
Breast International Group 
Berufsverband Niedergelassener Gynakologischer Onkologen  
Breast International Group 
European Society of Breast Cancer Specialists 
European Organisation for Research and Treatment of Cancer 
Grupo Español de Investigación en Cáncer de Mama 
Gruppo Italiano Mammella (GIM) 
Hellenic Society of Breast Surgeons 
International Breast Cancer Study Group 
International Collaborative Cancer Group 
Italian Trials in Medical Oncology 
National Cancer Research Institute 
The Netherlands Association for Medical Education 
Priv-Doz Dr Med Marc Thill 
The Swedish Association of Breast Oncologists  
Grupo Español de Estudio, Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos 
United Kingdom Breast Intergroup  
Central and Eastern European Oncology Group 
European Society of Surgical Oncology 
Austrian Breast & Colorectal Cancer Study Group 
West German Study Group 
Sociedad Mexicana de Oncología 
Asociación Mexicana de Mastología 
Sociedad Argentina de Mastología 
Sociedade Brasileira de Oncologia Clínica 
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Figure Legends 
 
Figure 1. Likelihood of adjuvant chemotherapy recommendations stratified by country. Each 
practicing clinician was asked to make treatment recommendations for 24 randomly selected patient 
profiles (chemotherapy, endocrine treatment alone, or a request for more information). Based on 
their treatment recommendations a simulation model was generated to predict the probability for 
each treatment recommendation for 896 simulated patient profiles.  
 
 
Figure 2. Graphic representation of a conjoint analysis of adjuvant chemotherapy recommendations. 
The y-axis depicts a ranking of importance of various clinical and pathologic characteristics with 
regard to recommendation of chemotherapy. The x-axis depicts the index of importance for each 
patient characteristic. The relative distance between the levels indicates the relative impact on the 
recommendation. Interaction effects between the characteristics have not been considered in these 
analyses. ER, estrogen receptor; N0, lymph node negative; N1, 1–3 affected lymph nodes; PR, 
progesterone receptor. 
 
 
Figure 3. Ranking of 672 simulated breast cancer patient profiles according to their likelihood for an 
adjuvant chemotherapy or endocrine treatment alone recommendation. Patient profiles having the 
biologically uncommon combination of low ER expression and high PR expression or >20% Ki67+ 
tumor cells in a Grade 1 or 2 tumor were excluded from this analysis. Grey cells (n=43) show patient 
profiles with ≥75% probability to be recommended endocrine treatment alone. Orange cells (n=99) 
show patient profiles with 50%–75% probability to be recommended endocrine treatment alone. 
Purple cells (n=104) show patient profiles with <50% probability to be recommended endocrine 
treatment alone AND <50% probability to be recommended chemotherapy. Green cells (n=145) 
show patient profiles with 50%–75% probability to be recommended chemotherapy. Blue cells 
(n=281) show patient profiles with ≥75% probability to be recommended chemotherapy. ER, 
estrogen receptor; HR, hormone receptor; N0, lymph node negative; N1, 1–3 affected lymph nodes; 
PR, progesterone receptor. 
 
 
Figure 4. (A) Usage of multigene assays and desire to use multigene assays for practicing clinicians by 
country. (B) Type of multigene assays that were used (multiple answers were allowed; only 
practicing clinicians who indicated to use multigene assays were considered). (C) Reasons for not 
using multigene assays (multiple answers were allowed; only practicing clinicians who indicated to 
not use multigene assays were considered). 
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Tables 
 
Table 1. Demographics and general practice patterns of MAGIC survey respondents. 
 
 All 
respondents 
(n=911) 
Medical 
oncologists 
(n=495) 
Gynecologists 
(n=147) 
Radiation 
oncologists 
(n=38) 
Surgical 
oncologists 
(n=192) 
Pathologists 
(n=32)a 
Other (n=7) 
Region of residence, n(%)b 
 Europe 672 (74) 392 (79) 85 (58) 32 (84) 132 (69) 25 (78) 6 (86) 
 Latin America 157 (17) 44 (9) 62 (42) 4 (11) 45 (23) 1 (3) 1 (14) 
 Russia 56 (6) 46 (9) 0 (0) 0 (0) 5 (3) 5 (16) 0 (0) 
 Rest of World 26 (3) 13 (3) 0 (0) 2 (5) 10 (5) 1 (3) 0 (0) 
Experience, n (%) 
 ≥10 Years of experiencec 720 (79) 392 (79) 111 (76) 34 (89) 157 (82) 23 (72) 3 (43) 
 Chemotherapy prescriber 613 (67) 492 (99) 66 (45) 19 (50) 32 (17) 2 (6) 2 (29) 
 Number of new patients/yeard 113 (150) 104 (97) 97 (73) 125 (125) 146 (266) 641 (719) 76 (58) 
Involvement of multidisciplinary team, n(%)a 
 Always 756 (83) 407 (82) 113 (77) 34 (89) 172 (90) 25 (96) 5 (71) 
 In some cases 140 (15) 86 (17) 27 (18) 4 (11) 20 (10) 1 (4) 2 (29) 
 Never 9 (1) 2 (0.4) 7 (5) 0 (0) 0 (0) 0 (0) 0 (0) 
Guidelines adherence, n(%)a 
 Always 496 (55) 251 (51) 86 (59) 19 (50) 123 (64) 14 (54) 3 (43) 
 Often 389 (43) 234 (47) 60 (41) 16 (42) 64 (33) 12 (46) 3 (43) 
 Sometimes 15 (2) 8 (2) 0 (0) 3 (8) 4 (2) 0 (0) 0 (0) 
 Never 5 (1) 2 (0.4) 1 (1) 0 (0) 1 (1) 0 (0) 1 (14) 
Guidelines used, n(%)a,e  
 St. Gallen17  353 (71) 179 (71) 63 (73) 18 (95) 82 (67) 11 (79) 0 (0) 
 ESMO6  205 (41) 131 (52) 21 (24) 10 (53) 35 (28) 7 (50) 1 (33) 
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 ASCO18 218 (44) 115 (46) 38 (44) 9 (47) 45 (37) 9 (64) 2 (67) 
 NCCN7  272 (55) 138 (55) 42 (49) 10 (53) 74 (60) 7 (50) 1 (33) 
Tools/nomograms used, n(%)a 
 Nottingham Prognostic Index19 209 (23) 86 (17) 23 (16) 9 (24) 69 (36) 17 (65) 5 (71) 
 Adjuvant! Online20  644 (71) 363 (73) 96 (65) 32 (84) 135 (70) 15 (58) 3 (43) 
 Predict21  109 (12) 59 (12) 15 (10) 9 (24) 23 (12) 2 (8) 1 (14) 
 No use of tools/nomograms 134 (15) 73 (15) 38 (26) 1 (3) 19 (10) 2 (8) 1 (14) 
Consideration of Ki67, n(%)a 
 Strong consideration  265 (29) 156 (32) 48 (33) 6 (16) 46 (24) 8 (31) 1 (14) 
 Not a predominant consideration 497 (55) 275 (56) 78 (53) 21 (55) 108 (56) 13 (50) 2 (29) 
 Little influence 48 (5) 20 (4) 14 (10) 2 (5) 10 (5) 1 (4) 1 (14) 
 Not considered 34 (4) 13 (3) 7 (5) 2 (5) 7 (4) 4 (15) 1 (14) 
 No access to Ki67 testing 61 (7) 31 (6) 0 (0) 7 (18) 21 (11) 0 (0) 2 (29) 
ASCO, American Society of Clinical Oncology; ER, estrogen receptor; ESMO, European Society for Medical Oncology; HER2, human epidermal growth factor receptor 2; NCCN, National 
Comprehensive Cancer Network; PR, progesterone receptor. 
Due to rounding of the numbers, total percentages may not equal 100%. 
a
For the categories “Involvement of multidisciplinary team,” “Guidelines adherence,” “Guidelines used,” “Tools/nomograms used,” and “Consideration of Ki67,” data were missing for 6 
pathologists.  
b
Countries with more than 30 respondents were: Argentina, Belgium, Switzerland, Germany, Spain, France, Greece, Hungary, Italy, Mexico, The Netherlands, Russia, Sweden, and the United 
Kingdom.  
c
For practicing clinicians, the number of years of experience in treating breast cancer was considered. For pathologists, the number of years in which they were involved in running diagnostic 
tests for breast cancer patients was considered. 
d
For practicing clinicians, the number of new breast cancer patients per year treated by the respondent was considered. For pathologists, the number of breast cancer patients per year for 
which the respondent runs ER/PR/HER2 immunohistochemistry was considered. For both, “mean (standard deviation)” are shown. 
e
Only respondents who indicated to always use breast cancer treatment guidelines were considered. 
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Table 2. Consideration by practicing clinicians of traditional patient characteristics for adjuvant chemotherapy recommendations. Practicing clinicians 
indicated at which level of the respective clinical or histopathologic markers they would strongly consider to recommend adjuvant chemotherapy to HR+, 
HER2– early breast cancer patients.  
 
 All 
N=879 
AR 
N=66 
BE 
N=45 
CH 
N=29 
DE 
N=54 
ES 
N=75 
FR 
N=63 
GR 
N=45 
HU 
N=28 
IT 
N=103 
MX 
N=52 
NL 
N=27 
RU 
N=52 
SE 
N=31 
UK 
N=67 
In a node-negative context, is there a specific tumor size above which you would strongly consider using adjuvant chemotherapy? 
 >1 cm 14 39 0 3 6 11 8 11 11 4 37 22 8 10 3 
 >2 cm 35 39 42 10 26 49 48 36 50 31 31 52 29 32 34 
 >3 cm 14 8 16 10 9 16 14 24 14 17 8 15 2 23 31 
 >4 cm 5 6 7 7 0 1 6 7 11 1 4 0 2 3 12 
 >5 cm 9 5 11 38 11 8 3 4 0 6 15 4 12 26 7 
 Tumor size does not affect 
decision 
22 3 24 31 48 15 21 18 14 42 6 7 48 6 12 
In a node-negative context, is there a specific tumor grade above which you would strongly consider using adjuvant chemotherapy? 
 Grade ≥1 1 0 0 0 0 0 0 0 0 0 0 0 4 0 0 
 Grade ≥2 21 6 16 10 13 25 25 42 32 10 29 44 35 19 24 
 Grade 3 70 86 80 79 81 71 68 53 64 79 56 56 44 81 73 
 Tumor grade does not affect 
decision 
8 8 4 10 6 4 6 4 4 12 15 0 17 0 3 
What percentage of ER+ cells would you consider low and would make you strongly consider using adjuvant chemotherapy in addition to hormonal 
therapy? 
 <1% 26 61 16 28 52 19 17 24 11 22 25 22 25 0 12 
 <10% 47 30 49 38 35 45 65 44 54 45 44 56 44 84 43 
 <30% 20 6 27 34 4 29 10 24 32 25 17 11 15 10 39 
 Percentage of ER+ cells does not 
affect decision 
7 3 9 0 9 7 8 7 4 8 13 11 15 6 6 
At which Ki67 percentage would you strongly consider giving adjuvant chemotherapy? 
 ≥14%  27 28 36 10 13 43 18 33 14 20 35 17 40 6 21 
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 >20%  34 31 36 48 56 31 44 36 46 37 21 17 28 45 11 
 >30%  32 31 27 38 26 27 31 29 39 39 38 17 21 42 53 
 Ki67 expression does not affect 
decision 
7 10 2 3 6 0 8 2 0 4 6 50 11 6 16 
What number of positive axillary nodes would make you strongly consider giving chemotherapy? 
 Lymph node negative 4 0 0 3 2 5 2 2 0 4 10 4 4 6 6 
 1a  39 61 27 3 22 43 40 42 39 23 48 59 58 48 34 
 2 21 17 27 14 20 25 22 24 29 18 10 15 8 35 34 
 3 11 12 16 31 22 3 14 7 7 15 13 0 10 0 6 
 ≥4 21 8 29 45 31 13 19 22 21 33 19 15 13 6 10 
 Number of positive lymph nodes 
does not affect decision 
5 3 2 3 2 11 3 2 4 7 0 7 8 3 9 
Is there an upper age limit above which you would strongly consider not giving adjuvant chemotherapy? 
 >50 years 1 3 0 0 2 1 0 2 0 5 0 0 2 0 0 
 >60 years 1 0 0 3 0 0 3 2 4 0 0 4 0 0 0 
 >70 years 17 29 11 7 11 12 21 13 14 8 15 52 15 6 19 
 >80 years 48 52 53 62 39 60 41 36 57 51 33 33 38 77 61 
 Age does not affect decision 33 17 36 28 48 27 35 47 25 36 52 11 44 16 19 
AR, Argentina, BE, Belgium; CH, Switzerland; DE, Germany; ER, estrogen receptor; ES, Spain; FR, France; GR, Greece; HER2, human epidermal growth factor receptor; HR, hormone receptor; 
HU, Hungary; IT, Italy; MX, Mexico; NL, The Netherlands; RU, Russia; SE, Sweden; UK, United Kingdom. 
Due to rounding of the numbers, total percentages may not equal 100%. Country-specific data are shown for countries with ≥30 respondents. 
a
Including isolated tumor cells or nodal micrometastases. 
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Table 3. Multigene assays – guideline recommendations. 
 
Source 
Oncotype DX 
(21-gene RT-PCR assay) 
MammaPrint 
(70-gene expression profile) 
Other multigene assays 
NCCN7   An option when 
evaluating patients with 
primary tumors 
characterized as 
─ 0.6 to 1.0 cm 
─ Unfavorable 
features or >1 cm 
─ Node negative, 
HR+, and HER2– 
(category 2A) 
 The RS may assist in 
estimating likelihood of 
recurrence and benefit 
from chemotherapy  
 
 FDA-approved for 
identifying patients with 
ER+ or ER− breast cancer 
as having a high or low 
risk of recurrence 
 Not approved for 
predicting benefit from 
adjuvant systemic 
therapy 
 
 
 Currently insufficient 
evidence to warrant 
inclusion in the 
guidelines 
 
ESMO6   Recommended for obtaining extra prognostic and/or 
predictive information that is used to complement 
pathology assessment 
 May be used to predict response to adjuvant 
chemotherapy 
  
 Not specifically 
addressed 
 
St. Gallen5   Provides prognostic and 
predictive information 
(years 1–5 and >5) 
regarding usefulness of 
adjuvant chemotherapy in 
patients with luminal 
 Has prognostic utility 
regarding adjuvant 
chemotherapy in years 
1–5. Panel rejected the 
prognostic value 
 PAM-50 ROR score, 
EndoPredict, and the 
Breast Cancer Index 
considered to be 
prognostic in years 1–5. 
The panel was equally 
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disease. Beyond 5 years, 
the Panel was divided 
almost equally on the 
prognostic value of 
Oncotype DX 
beyond 5 years divided with regard to 
the prognostic value for 
EndoPredict, Breast 
Cancer Index in years 5-
10 but acknowledged 
the prognostic value of 
PAM-50 ROR in years 5-
10. 
ASCO23   For use in newly 
diagnosed patients with 
node-negative, ER+ breast 
cancer 
 Can identify patients who 
are predicted to obtain 
the most therapeutic 
benefit from adjuvant 
tamoxifen and may not 
require adjuvant 
chemotherapy 
 High RS appears to be 
predictive of benefit with 
adjuvant chemotherapy  
 
 The clinical utility of other assays is under investigation 
 
ASCO, American Society of Clinical Oncology; ER, estrogen receptor; ESMO, European Society for Medical Oncology; FDA, US Food and Drug Administration; HER2, human epidermal growth 
factor receptor 2; HR, hormone receptor; NCCN, National Comprehensive Cancer Network; RS, recurrence score; ROR, risk of recurrence; RT-PCR, reverse transcription polymerase chain 
reaction. 
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Supplementary Table 1. Reasons for not using multigene assays, stratified by country. 
 
 All 
N=389 
AR 
N=13 
BE 
N=28 
CH 
N=13 
DE 
N=6 
ES 
N=16 
FR 
N=37 
GR 
N=3 
HU 
N=12 
IT 
N=82 
MX 
N=11 
NL 
N=3 
RU 
N=34 
SE 
N=31 
UK 
N=42 
Lack of reimbursement 45% 0% 68% 85% 67% 63% 70% 67% 67% 60% 9% 33% 15% 6% 33% 
Price 44% 92% 43% 8% 33% 25% 49% 67% 75% 33% 91% 0% 15% 39% 52% 
Lack of availability 39% 31% 25% 15% 0% 31% 14% 67% 33% 38% 55% 0% 71% 29% 60% 
Not in relevant guidelines 20% 0% 21% 0% 67% 6% 32% 0% 8% 17% 0% 0% 32% 45% 21% 
Lack of evidence 17% 8% 29% 38% 67% 6% 22% 0% 8% 12% 0% 67% 3% 39% 19% 
Other 2% 0% 4% 8% 0% 0% 3% 0% 0% 0% 0% 0% 0% 10% 0% 
AR, Argentina, BE, Belgium; CH, Switzerland; DE, Germany; ES, Spain; FR, France; GR, Greece; HU, Hungary; IT, Italy; MX, Mexico; NL, The Netherlands; RU, Russia; SE, Sweden; UK, United 
Kingdom. 
Data show the percentage of practicing clinicians who indicated to not use multigene assays (multiple answers were allowed). Country-specific data are shown for countries with ≥30 
respondents.  
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Supplementary Table 2. Multigene assays used, stratified by country (multiple answers allowed). 
 
 All 
N=471 
AR 
N=52 
BE 
N=16 
CH 
N=16 
DE 
N=48 
ES 
N=59 
FR 
N=26 
GR 
N=41 
HU 
N=15 
IT 
N=20 
MX 
N=41 
NL 
N=24 
RU 
N=10 
UK 
N=22 
Oncotype DX® Breast Cancer Assay 81% 94% 56% 94% 77% 69% 88% 100% 93% 70% 78% 17% 50% 100% 
MammaPrint® 35% 25% 31% 19% 4% 73% 8% 7% 7% 50% 73% 96% 20% 9% 
EndoPredict® 7% 0% 13% 25% 44% 0% 0% 0% 0% 0% 2% 0% 10% 0% 
FEMTELLE® 5% 0% 0% 0% 38% 0% 15% 2% 0% 0% 0% 0% 10% 0% 
Prosigna 2% 0% 0% 0% 0% 10% 4% 0% 0% 5% 2% 0% 20% 0% 
Mammostrat® 1% 4% 0% 0% 0% 0% 0% 0% 7% 0% 5% 0% 0% 0% 
Other multigene assay 2% 0% 31% 6% 2% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
AR, Argentina, BE, Belgium; CH, Switzerland; DE, Germany; ES, Spain; FR, France; GR, Greece; HU, Hungary; IT, Italy; MX, Mexico; NL, The Netherlands; RU, Russia; SE, Sweden; UK, United 
Kingdom. 
Data show the percentage of practicing clinicians who use multigene assays who indicated to use the described multigene assay. Country-specific data are shown for countries with ≥30 
respondents. Sweden was not included in this analysis as none of the Swedish respondents indicated to use multigene assays. 
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